featured
Front-Line Venetoclax and Rituximab for Young and Fit Patients With CLL and an Adverse Biologic Profile
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study
Haematologica 2023 Jan 12;[EPub Ahead of Print], FR Mauro, ID Starza, M Messina, G Reda, L Trentin, M Coscia, P Sportoletti, L Orsucci, V Arena, GM Casaluci, R Marasca, R Murru, L Laurenti, F Ilariucci, C Stelitano, D Mannina, M Massaia, GM Rigolin, L Scarfò, M Marchetti, L Levato, M Tani, A Arcari, G Musuraca, M Deodato, P Galieni, VB Patrizi, D Gottardi, AM Liberati, A Giordano, MC Molinari, D Pietrasanta, V Mattiello, A Visentin, C Vitale, F Albano, A Neri, LA De Novi, MS De Propris, M Nanni, I Del Giudice, A Guarini, P Fazi, M Vignetti, A Piciocchi, A Cuneo, R FoàFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.